论文部分内容阅读
目的探讨可溶性CD23在子宫内膜异位症(内异症)诊断和分期中的意义。方法 2009年10月至2010年10月在吉林医药学院附属吉林油田总医院采用ELISA法对内异症患者组和对照组血清和腹腔液中可溶性CD23(sCD23)的含量进行测定,并与内异症严重程度进行相关性分析。结果子宫内膜异位症组腹腔液中sCD23含量(4.55±1.11)μg/L明显高于对照组(1.52±0.45)μg/L(P<0.05),而血清sCD23水平子宫内膜异位症组(54.77±7.23)μg/L与对照组(58.83±5.65)μg/L比较差异无统计学意义(P>0.05)。不同分期的子宫内膜异位症患者之间血清和腹腔液sCD23含量比较差异无统计学意义(P>0.05)。结论 sCD23在内异症局部免疫异常过程中可能发挥作用。
Objective To investigate the significance of soluble CD23 in the diagnosis and staging of endometriosis (endometriosis). Methods The levels of soluble CD23 (sCD23) in serum and peritoneal fluid of patients with endometriosis and control group were measured by ELISA at Jilin Oilfield General Hospital Affiliated to Jilin Medical College from October 2009 to October 2010, Serum severity correlation analysis. Results The sCD23 level in peritoneal fluid of endometriosis group (4.55 ± 1.11) μg / L was significantly higher than that of control group (1.52 ± 0.45) μg / L (P <0.05), while serum sCD23 level of endometriosis (54.77 ± 7.23) μg / L compared with the control group (58.83 ± 5.65) μg / L, there was no significant difference (P> 0.05). There was no significant difference in sCD23 levels in serum and peritoneal fluid between patients with different stages of endometriosis (P> 0.05). Conclusion sCD23 may play an important role in the process of local immune abnormalities.